"To date, there is no evidence that an adaptation of BioNTech's current Covid-19 vaccine against key identified emerging variants is necessary," the company said in a statement.
German firm BioNTech
said Monday that the Covid
it developed with Pfizer
does not require any modifications at the moment to protect against variants of the virus.
"To date, there is no evidence that an adaptation of BioNTech
's current Covid
against key identified emerging variants is necessary," the company said in a statement.
Nevertheless, in preparations for a need at some point to make tweaks to its current vaccine
, the company said it began tests in March on a "modified, variant-specific version" of its jabs.
"The aim of this study is to explore the regulatory pathway that BioNTech
would pursue if SARS-CoV-2 were to change enough to require an updated vaccine
," it said.
An assessment is also ongoing on the impact of a possible third dose in prolonging immunity and in protecting against variants.
chief executive Ugur Sahin had said in April that the vaccine
works against the Indian variant.
was the first to win authorisation in the West, and has since been deployed in dozens of countries worldwide.
It is now supplying more than 90 countries worldwide and is expecting to ramp up its production to up to three billion doses by the end of the year from 2.5 billion doses expected previously.